Successful TFR in DASFREE: dasatinib for R/R CML

Michael Mauro, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the outcome of the DASFREE trial (NCT01850004), which monitored the use of dasatinib in patients with chronic myeloid leukemia (CML) showing resistance or intolerance to previous TKI treatments. In this study, the patient population was split into those taking dasatinib as a primary or secondary treatment. Dr Mauro explains the successful treatment-free remission (TFR) results and how patients were able to obtain deep molecular responses during the trial. He expresses how this study is only the beginning and that the next step will be research into managing TFR in patients, regardless of which TKIs they are taking.